144 related articles for article (PubMed ID: 34789400)
1. The prognostic value of antibodies to gp210 among patients with primary biliary cholangitis in Northeast China.
Chen Q; Zhong R; Dong K; Wang Y; Kui Y; Ma B; Wen X; Jin Q
Dig Liver Dis; 2022 Aug; 54(8):1094-1100. PubMed ID: 34789400
[TBL] [Abstract][Full Text] [Related]
2. Anti-gp210-positive primary biliary cholangitis: The dilemma of clinical treatment and emerging mechanisms.
Wang X; Yang Z; Ran Y; Li L; Wang B; Zhou L
Ann Hepatol; 2023; 28(5):101121. PubMed ID: 37302574
[TBL] [Abstract][Full Text] [Related]
3. Antibodies to gp210 and understanding risk in patients with primary biliary cholangitis.
Haldar D; Janmohamed A; Plant T; Davidson M; Norman H; Russell E; Serevina O; Chung K; Qamar K; Gunson B; Hansen B; Richter A; Trivedi PJ; Hirschfield GM
Liver Int; 2021 Mar; 41(3):535-544. PubMed ID: 33022821
[TBL] [Abstract][Full Text] [Related]
4. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis.
Harms MH; van Buuren HR; Corpechot C; Thorburn D; Janssen HLA; Lindor KD; Hirschfield GM; Parés A; Floreani A; Mayo MJ; Invernizzi P; Battezzati PM; Nevens F; Ponsioen CY; Mason AL; Kowdley KV; Lammers WJ; Hansen BE; van der Meer AJ
J Hepatol; 2019 Aug; 71(2):357-365. PubMed ID: 30980847
[TBL] [Abstract][Full Text] [Related]
5. Clinical performance of AMA-M2, anti-gp210 and anti-sp100 antibody levels in primary biliary cholangitis: When detected by multiplex bead-based flow fluorescent immunoassay.
Wang Z; Li Y; Ren L; Li Y; Xu T; Li W; Gao W; Sun G; Liu M
Immun Inflamm Dis; 2024 Jan; 12(1):e1161. PubMed ID: 38270327
[TBL] [Abstract][Full Text] [Related]
6. Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis.
Nakamura M; Shimizu-Yoshida Y; Takii Y; Komori A; Yokoyama T; Ueki T; Daikoku M; Yano K; Matsumoto T; Migita K; Yatsuhashi H; Ito M; Masaki N; Adachi H; Watanabe Y; Nakamura Y; Saoshiro T; Sodeyama T; Koga M; Shimoda S; Ishibashi H
J Hepatol; 2005 Mar; 42(3):386-92. PubMed ID: 15710222
[TBL] [Abstract][Full Text] [Related]
7. Treatment of primary biliary cholangitis with ursodeoxycholic acid, prednisolone and immunosuppressants in patients not responding to ursodeoxycholic acid alone and the prognostic indicators.
Qian JD; Yao TT; Wang Y; Wang GQ
Clin Res Hepatol Gastroenterol; 2020 Nov; 44(6):874-884. PubMed ID: 32305248
[TBL] [Abstract][Full Text] [Related]
8. The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210.
Yang F; Yang Y; Wang Q; Wang Z; Miao Q; Xiao X; Wei Y; Bian Z; Sheng L; Chen X; Qiu D; Fang J; Tang R; Gershwin ME; Ma X
Aliment Pharmacol Ther; 2017 Mar; 45(5):733-743. PubMed ID: 28083929
[TBL] [Abstract][Full Text] [Related]
9. Early Prognostic Utility of Gp210 Antibody-Positive Rate in Primary Biliary Cholangitis: A Meta-Analysis.
Huang C; Han W; Wang C; Liu Y; Chen Y; Duan Z
Dis Markers; 2019; 2019():9121207. PubMed ID: 31737133
[TBL] [Abstract][Full Text] [Related]
10. Prognosis of 732 ursodeoxycholic acid-treated patients with primary biliary cholangitis: A single center follow-up study from China.
Chen S; Duan W; Li M; Li S; Lv T; Tian Q; Wang Q; Wu X; Zhao X; Wang X; Wang Y; Kong Y; Ma H; Ou X; You H; Jia J
J Gastroenterol Hepatol; 2019 Jul; 34(7):1236-1241. PubMed ID: 30365184
[TBL] [Abstract][Full Text] [Related]
11. Ursodeoxycholic Acid Therapy in Patients with Primary Biliary Cholangitis with Limited Liver Transplantation Availability.
Melchor-Mendoza YK; Martínez-Benítez B; Mina-Hawat A; Rodríguez-Leal G; Duque X; Moran-Villota S
Ann Hepatol; 2017; 16(3):430-435. PubMed ID: 28425413
[TBL] [Abstract][Full Text] [Related]
12. [Study of clinical characteristics in patients with gp210 antibody-positive primary biliary cholangitis].
Huang CY; Liu YM; Liu H; Xu B; Yan HP; Zhang HP; Liao HY; Zhang XD; Zhao J; Li WJ; Duan ZP
Zhonghua Gan Zang Bing Za Zhi; 2022 Apr; 30(4):419-425. PubMed ID: 35545568
[No Abstract] [Full Text] [Related]
13. Obeticholic acid for the treatment of primary biliary cholangitis.
Ali AH; Lindor KD
Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
[TBL] [Abstract][Full Text] [Related]
14. Anti-gp210 and anti-Sp100 antibodies in primary biliary cholangitis.
Ben Lamine Z; Ben Jazia I; Ben Ahmed M; Ben Slama A; Baccouche A; Slama F; Jemaa A; Ghedira I; Mankaï A
Arab J Gastroenterol; 2021 Dec; 22(4):316-320. PubMed ID: 34090832
[TBL] [Abstract][Full Text] [Related]
15. Novel Anti-Hexokinase 1 Antibodies Are Associated With Poor Prognosis in Patients With Primary Biliary Cholangitis.
Reig A; Norman GL; Garcia M; Shums Z; Ruiz-Gaspà S; Bentow C; Mahler M; Romera MA; Vinas O; Pares A
Am J Gastroenterol; 2020 Oct; 115(10):1634-1641. PubMed ID: 32467507
[TBL] [Abstract][Full Text] [Related]
16. Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis.
Tanaka A; Hirohara J; Nakano T; Matsumoto K; Chazouillères O; Takikawa H; Hansen BE; Carrat F; Corpechot C
J Hepatol; 2021 Sep; 75(3):565-571. PubMed ID: 33882268
[TBL] [Abstract][Full Text] [Related]
17. Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis.
Corpechot C; Chazouillères O; Belnou P; Montano-Loza AJ; Mason A; Ebadi M; Eurich D; Chopra S; Jacob D; Schramm C; Sterneck M; Bruns T; Reuken P; Rauchfuss F; Roccarina D; Thorburn D; Gerussi A; Trivedi P; Hirschfield G; McDowell P; Nevens F; Boillot O; Bosch A; Giostra E; Conti F; Poupon R; Parés A; Reig A; Donato MF; Malinverno F; Floreani A; Russo FP; Cazzagon N; Verhelst X; Goet J; Harms M; van Buuren H; Hansen B; Carrat F; Dumortier J;
J Hepatol; 2020 Sep; 73(3):559-565. PubMed ID: 32275981
[TBL] [Abstract][Full Text] [Related]
18. Presence of anti-gp210 or anti-sp100 antibodies in AMA-positive patients may help support a diagnosis of primary biliary cholangitis.
Jaskowski TD; Nandakumar V; Novis CL; Palmer M; Tebo AE
Clin Chim Acta; 2023 Feb; 540():117219. PubMed ID: 36610465
[TBL] [Abstract][Full Text] [Related]
19. Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis.
Efe C; Taşçilar K; Henriksson I; Lytvyak E; Alalkim F; Trivedi H; Eren F; Eliasson J; Beretta-Piccoli BT; Fischer J; Calişkan AR; Chayanupatkul M; Coppo C; Ytting H; Purnak T; Muratori L; Werner M; Muratori P; Rorsman F; Önnerhag K; Günşar F; Nilsson E; Heurgué-Berlot A; Güzelbulut F; Demir N; Gönen C; Semela D; Aladağ M; Kiyici M; Schiano TD; Montano-Loza AJ; Berg T; Ozaslan E; Yoshida EM; Bonder A; Marschall HU; Wahlin S
Am J Gastroenterol; 2019 Jul; 114(7):1101-1108. PubMed ID: 31241547
[TBL] [Abstract][Full Text] [Related]
20. Fluctuations of antimitochondrial antibodies and anti-gp210 antibody in a patient with primary biliary cholangitis and Sjögren syndrome with subsequent autoimmune hemolytic anemia: A case report.
Zhao DT; Liu YM; Han Y; Zhang HP; Zhao Y; Yan HP
Medicine (Baltimore); 2020 Jan; 99(3):e18856. PubMed ID: 32011506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
